European Journal of Medicinal Chemistry (2020)
Update date:2022-08-16
Topics:
Chen, Yun
Bai, Gang
Ning, Yi
Cai, Shi
Zhang, Tao
Song, Peiran
Zhou, Jinpei
Duan, Wenhu
Ding, Jian
Xie, Hua
Zhang, Huibin
Harboring MYD88 L265P mutation triggers tumors growth through the activation of NF-κB by interleukin-1 receptor associated kinase 4 (IRAK4) in diffuse large B-cell lymphoma (DLBCL), highlighting IRAK4 as a therapeutic target for tumors driven by aberrant MYD88 signaling. Herein, we report the design, synthesis, and structure?activity relationships of imidazo[1,2-b]pyridazines as potent IRAK4 inhibitors. The representative compound 5 exhibited excellent IRAK4 potency (IRAK4 IC50 = 1.3 nM) and favorable kinase selectivity profile. It demonstrated cellular selectivity for activated B cell–like (ABC) subtype DLBCL with MYD88 L265P mutation in cytotoxicity assay. The kinase inhibitory efficiency of compound 5 was further validated by Western blot analysis of phosphorylation of IRAK4 and downstream signaling in OCI-LY10 and TMD8 cells. Besides, combination of compound 5 and BTK inhibitor ibrutinib synergistically reduced the viability of TMD8 cells. These results indicated that compound 5 could be a promising IRAK4 inhibitor for the treatment of mutant MYD88 DLBCL.
View MoreWENZHOU M&C FOREIGN TRADE CO.,LTD.
Contact:+86-577-88862917
Address:No.8 Liming West Road,Wenzhou,zhejiang,China
Alpha(shijiazhuang) Chemical Co., Ltd
Contact:+86-311-85652680
Address:Shijiazhuang City ,Hebei Province China
Beijing Cooperate Pharmaceutical Co.,Ltd
Contact:86-01060279497
Address:No.507,Building 4,Tianhua Street, Biomedicine industrial Base
Fujian Huitian Biological Pharmacy Co., Ltd.
Contact:0086-598-8300831; 8339920
Address:No.46,Taijiang Road,Sanming City,Fujian,China
Changzhou Medi-tech Bioscientific Co., Ltd.
Contact:86-519-83246372
Address:Number 115 Menghedadao Road, Changzhou, Jiangsu, China
Doi:10.1080/10715762.2019.1683171
(2019)Doi:10.1111/j.2042-7158.1993.tb05586.x
(1993)Doi:10.1039/js8742700404
()Doi:10.1016/0040-4039(88)85254-7
(1988)Doi:10.1039/c4ra05572a
(2014)Doi:10.1021/ja00766a048
(1972)